Trials / Completed
CompletedNCT00570726
Treatment of Failing Blebs With Ranibizumab
Effect of Needle Bleb Revision With Ranibizumab as a Primary Intervention in a Failing Bleb Following Trabeculectomy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- The New York Eye & Ear Infirmary · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- —
Summary
This study was designed to evaluate the efficacy and safety in the use of Ranibizumab, an effective vascular endothelial growth factor (VGEF) inhibitor, in treating patients with a failing bleb, characterized by increased fibrosis and vascularization of the conjuctiva, following trabeculectomy. Six subjects from one site will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab (Lucentis) |
Timeline
- Start date
- 2000-06-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2007-12-11
- Last updated
- 2014-10-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00570726. Inclusion in this directory is not an endorsement.